2019-12-03| Asia-Pacific

Weekly in Asia|Nov-3

by GeneOnline
Share To


Innovative PD-1 Inhibitor Tyvyt® (Sintilimab) Now Included in the New Catalogue of National Reimbursement Drug List (NRDL)

On November 28, Innovent Biologics, Inc. and Eli Lilly and Company jointly announced that the innovative PD-1 inhibitor Tyvyt® (sintilimab injection), co-developed by both companies, has become the only PD-1 inhibitor ever included in the new Catalogue of National Reimbursement Drug List (NRDL).

The inclusion of Tyvyt® (sintilimab injection) to the NRDL demonstrates that the National Healthcare Security Administration (NHSA) has recognized its clinical value, patients benefit and novelty among other factors. This will also allow more patients to be able to afford the new immunotherapy drugs to improve their lives.

About Innovent

Established in 2011, Innovent is a Chinese biopharmaceutical company committed to developing, manufacturing and commercializing high quality innovative medicines for the treatment of major diseases in the fields of oncology, ophthalmology, autoimmune, and cardiovascular diseases.


About Eli Lilly and Company

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. Eli Lilly products include neuroscience, endocrine, anti-infectives, cardiovascular agents, oncology, and animal health products.


JW Pharma Acquires C&C Research Laboratories

C&C Research Laboratories, the Korean first R&D joint venture corporation established in 1992 between Chugai and JW Pharmaceutical Corporation, has dedicated to the discovery and development of new drugs for years.

C&C has successfully created new drug candidates such as atopic dermatitis (JW1601) and gout (URC102), and has established its drug discovery platform.

On November 27, the two companies agreed to change the equity structure of C&C in the end of this year. During the term of this agreement, Chugai will sell its entire stake in C&C to JWP by December 31, 2019. C&C will become a wholly-owned subsidiary of JWP and continue its drug discovery research with independent management.

About Chugai

As an important member of the Roche Group, Chugai Pharmaceutical is one of Japan’s leading research-based pharmaceutical companies. Chugai is actively involved in the R&D of oncological drugs.


About JW Pharmaceutical Corporation

JW Pharmaceutical headquarters in Seocho-dong, Seoul. The company is one of the leading pharmaceutical companies in Korea with core competencies in antibiotics, and anti-cancer treatments.


Fujitsu Laboratories and Aichi Cancer Center Collaborate to Drive Advances in Cancer Genomic Medicine with AI

On November 29, Fujitlosu Laboratories Ltd. and Aichi Cancer Center successfully concluded a comprehensive cooperative research agreement to launch a newly developed AI technology to improve the efficiency of cancer genome information analysis and contribute to advances in the field of cancer genomic medicine. The joint research by Aichi Cancer Center and Fujitsu is expected to facilitate various AI technologies that offer the potential to innovate cancer genome medical care at Aichi Cancer Center and affiliated medical institutions.

About The Aichi Cancer Center in Japan

Aichi Cancer Center aims to establish a system that links the results of multigene panel testing for cancer to future, advanced medical care for cancer patients.


About Fujitsu Laboratories

Fujitsu Laboratories Ltd. offers development and research services. The Company provides research and technical support for human-centric computing, intelligent society, cloud fusion, and green data centers fields.



Genetron Health Receives China NMPA Approval for Clinical NGS

On December 2, Genetron Health, a China-based precision oncology company, announced that it has obtained the regulatory approval from the National Medical Products Association (NMPA) to launch its GENETRON S5 for clinical use.

The new desktop semiconductor-based next generation sequencing (NGS) system showcases Genetron Health’s ongoing commitment to providing early screening, diagnosis and treatment recommendations, as well as continuous monitoring and care services.

About Genetron Health

Beijing Genetron Health Genetic Technology Co. Ltd. manufactures medical equipment and operates software development, as well as import and export, and other businesses.



First Brain Bank in Singapore Launched to Reveal the Differences of Brain Disorders Between Races

There are significant differences in Caucasian and Asian brains, the way they are affected by neurological disorders thus differ.

Singapore recently set up its first brain bank, The Brain Bank Singapore, located in the Lee Kong Chian School of Medicine, Nanyang Technological University, to study this phenomenon.

The brain bank is the first of its kind in South-east Asia, with similar centers established in China, Europe and the United States. It is completely reliant on donors giving their brains post-mortem for research. Its initial goal is to collect 1,000 people to sign up as donors within the next four years.






© All rights reserved. Collaborate with us:
Related Post
Obesity Hope or Hype:Leveraging the Efficacy of Mainstream Weight Loss Pills (First Part)
Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications
Japan’s Red Biotechnology and International Business Partnering Take Spotlight on BioJapan 2023
Why NVIDIA’s CEO Huang Said AI Fostering Life Science:Highlighting GPU’s Applications in Biotech
Revolutionary AI-Powered Respiratory Monitor Maker Gets Financial Boost with Latest Funding
Researchers Predict Drug Interactions with Machine Learning to Enhance Patient Safety
USC-Led Study Reveals Benefits of Fasting-Mimicking Diet in Reducing Disease Risk and Slowing Aging
Astonishing brain tumour research wins the BIAL Award in Biomedicine 2023 worth 300,000 Euro
Targeted Cancer Therapy Breakthrough: Degrader-Antibody Conjugates (DACs) Advance to Clinical Trials
Degrader-Antibody Conjugates (DACs): Targeted Degradation for Therapeutics
Scroll to Top